Approval · Notice of Compliance 22514 · 2019
TECENTRIQ: Notice of Compliance 22514
Issued August 8, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22514
- Date
- August 8, 2019
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: tecentriq (atezolizumab) in combination with carboplatin and etoposide, is indicated for the first-linej treatment O9f adult patients with extensive-stage small cell lung cancer (es-sclc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TECENTRIQ | Not yet assigned | — |
Medicinal ingredients
- ATEZOLIZUMAB 60 MG per ML